The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...

The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...

Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 millionRaises ...

With five novel oral therapies in late-stage development, there could soon be a wide range of treatment options for relapsing–remitting multiple sclerosis, but better biomarkers are needed to more ...

Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple sclerosis (RMS), and is now being prepared for regulatory filings. The ...

Bristol Myers (BMY) faces a patent cliff, but a robust pipeline and CAR-T optionality plus 4.3% yield could spark upside—see ...

I'm excited to share that we kicked off 2025 with another strong quarter of performance, underscoring the sustained momentum ...

Awareness Month, Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) is bringing together the MS community through its ...

TG Therapeutics TGTX reported earnings of 17 cents per share (excluding the loss on extinguishment of debt) for the first ...

You can shed the kilos and normalise your blood tests, yet your immune cells may still act as if you were obese. Scientists ...

I was a approved for a certain amount then after talking to multiple customer services reps I was told that the card on file had a descripmency with expiration date. Then I was told I had to redo my ...